Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| MESO | 6-K | bullish | 5/10 | Mesoblast drew down US$50 million from a five-year non-dilutive facility provided by director Dr. Gregory George, at a f | Jun 25, 2026 |
| TWST | CLUSTER | neutral | 2/10 | Three Twist Bioscience insiders, including CEO Emily Leproust, sold a combined $203K in open-market transactions on June | Jun 25, 2026 |
| TSHA | PRESS-RELEASE | bearish | 7/10 | Taysha Gene Therapies announced the pricing of a $200M underwritten public offering of 32.5M shares at $6.00/share, plus | Jun 24, 2026 |
| IONS | 8-K | bullish | 7/10 | Ionis Pharmaceuticals announced FDA approval of TRYNGOLZA (olezarsen) for severe hypertriglyceridemia (sHTG), the first | Jun 24, 2026 |
| QURE | 144 | neutral | 2/10 | CEO Matthew C. Kapusta filed a Form 144 notice of intent to sell 6,696 ordinary shares valued at approximately $334,800. | Jun 24, 2026 |
| INDP | 8-K | bearish | 6/10 | Indaptus Therapeutics raised approximately $12 million through a private placement of 20 million shares at $0.60 per sha | Jun 24, 2026 |
| ELTX | 8-K | bullish | 6/10 | Elicio Therapeutics hosted a key opinion leader event on June 24, 2026, presenting data on three metastatic PDAC patient | Jun 24, 2026 |
| PGEN | 8-K | neutral | 3/10 | Precigen filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders held on June 18, 2026. Stockholde | Jun 24, 2026 |
| PASG | 8-K | bearish | 7/10 | Passage Bio entered into a definitive all-stock merger agreement with Remix Therapeutics, where pre-merger Passage share | Jun 24, 2026 |
| PASG | 425 | bearish | 7/10 | Passage Bio filed a definitive all-stock merger agreement to acquire Remix Therapeutics, where pre-merger Passage shareh | Jun 24, 2026 |
| HRMY | 144 | bearish | 5/10 | Former officer Sandip Kapadia filed a Form 144 notice of intent to sell 4,406 shares of Harmony Biosciences common stock | Jun 24, 2026 |
| JUSHF | 8-K | neutral | 2/10 | Jushi Holdings Inc. held its 2026 Annual General and Special Meeting on June 24, 2026, where shareholders overwhelmingly | Jun 24, 2026 |
| ABSI | 424B5 | mixed | 6/10 | Absci is conducting a $100M follow-on offering of 13.5M shares at $7.41 (market price), with Eli Lilly purchasing $40M o | Jun 24, 2026 |
| ABSI | 8-K | mixed | 5/10 | Absci Corp priced a $100 million underwritten offering of 13.5 million shares at $7.41 per share, with Eli Lilly committ | Jun 24, 2026 |
| REVB | 8-K | neutral | 4/10 | Revelation Biosciences filed an 8-K covering: (1) amended CEO/CFO employment agreements with enhanced change-in-control | Jun 24, 2026 |
| BBIO | 144 | neutral | 2/10 | BridgeBio Pharma director Randal Scott filed a Form 144 notice of intent to sell 2,196 shares of common stock, with an e | Jun 24, 2026 |
| QURE | 424B5 | mixed | 6/10 | uniQure priced a $225M underwritten public offering of 4,945,055 ordinary shares at $45.50/share, a ~7.2% discount to th | Jun 24, 2026 |
| VRAX | 6-K | neutral | 3/10 | Virax Biolabs Group Ltd announced a 1-for-25 reverse share split effective June 26, 2026, aimed at regaining compliance | Jun 24, 2026 |
| CGON | 144 | neutral | 2/10 | Director Leonard Post filed a Form 144 notice of intent to sell 5,000 shares of CG Oncology common stock, with an estima | Jun 24, 2026 |
| ADTX | 3 | neutral | 2/10 | HRT Financial LP filed an initial beneficial ownership statement (Form 3) for Aditxt, Inc., indicating a passive stake. | Jun 24, 2026 |
| APLM | 6-K | bearish | 7/10 | Apollomics received a Nasdaq deficiency notice for failing to maintain the minimum $35 million Market Value of Listed Se | Jun 24, 2026 |
| DFTX | 424B5 | bearish | 6/10 | Definium Therapeutics priced a 20.6M share follow-on offering at $34.00/share, raising ~$659M net proceeds (~$758M if un | Jun 24, 2026 |
| PASG | 425 | bearish | 7/10 | Passage Bio announced a definitive all-stock merger with Remix Therapeutics, where pre-merger Passage shareholders will | Jun 24, 2026 |
| KRRO | CLUSTER | bearish | 6/10 | Multiple insiders at Korro Bio sold shares totaling $2.3M over a 10-day window, led by director Jean Francois Formela wh | Jun 24, 2026 |
| DFTX | 8-K | bearish | 6/10 | Definium Therapeutics priced an upsized underwritten public offering of 20,588,236 common shares at $34.00 per share, wi | Jun 24, 2026 |
| APGE | CLUSTER | neutral | 6/10 | Two top insiders (CEO and CMO) sold a total of $14.1M in open-market transactions on June 22, 2026, just days after the | Jun 24, 2026 |
| EVMN | CLUSTER | neutral | 3/10 | Two C-suite insiders at Evommune (CEO and CSO) sold a combined $202K in open-market sales on June 22, 2026. The total re | Jun 24, 2026 |
| HCM | PRESS-RELEASE | bullish | 7/10 | HUTCHMED announced positive pivotal Phase II results for fanregratinib in FGFR2-fusion/rearrangement intrahepatic cholan | Jun 24, 2026 |
| CAPR | CLUSTER | neutral | 2/10 | Two Capricor Therapeutics insiders (CFO and EVP General Counsel) sold a combined $30K in open-market shares on June 22 a | Jun 24, 2026 |
| MRK | ANALYST-UPGRADE | bullish | 2/10 | CICC initiates coverage on MRK at Outperform | Jun 24, 2026 |